Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    Nanoparticle Albumin and einstein
Show Display Options
Rank Status Study
1 Withdrawn Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
Condition: Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Procedure: gene expression analysis;   Procedure: laboratory biomarker analysis;   Procedure: pharmacological study;   Procedure: polymerase chain reaction
2 Active, not recruiting
Has Results
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   HER2/Neu Positive;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIC Breast Cancer AJCC v6;   Stage IV Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Drug: Ixabepilone;   Biological: Bevacizumab;   Other: Questionnaire Administration;   Other: Laboratory Biomarker Analysis
3 Recruiting S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Conditions: Pancreatic Adenocarcinoma;   Resectable Pancreatic Carcinoma
Interventions: Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Oxaliplatin;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Procedure: Pancreatectomy

Study has passed its completion date and status has not been verified in more than two years.